Scientists have used a technique to grow bile duct organoids – often referred to as ‘mini-organs’ – in the lab and shown that these can be used to repair damaged human livers. This is the first time that the technique has been used on human organs.
Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published in Nature Medicine, the tiny laboratory models of tumours were used to identify a new drug that could potentially treat certain types of liver cancer.
Cambridge scientists have developed a new method for growing and transplanting artificial bile ducts that could in future be used to help treat liver disease in children, reducing the need for liver transplantation.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
There’s a nationwide shortage of suitable organs for transplanting – but what if some of those organs deemed ‘unsuitable’ could be rejuvenated? Researchers at Addenbrooke’s Hospital have managed just that – and last year gave two patients an unexpected Christmas present.
An experimental cystic fibrosis drug has been shown to prevent the disease’s damage to the liver, thanks to a world-first where scientists grew mini bile ducts in the lab.
DefiniGEN is one of the first commercial opportunities to arise from Cambridge’s expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic cells for drug screening.
Cambridge research that has for the first time successfully grown “mini-livers” from adult mouse stem cells has won the UK’s international prize for the scientific and technological advance with the most potential to replace, reduce or refine the use of animals in science (the 3Rs).
A new method for developing stem cells enables the production of liver and pancreatic cells in “clinically relevant” quantities for the first time, paving the way for regenerative therapies.
A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.
© 2024 University of Cambridge